BridgeMD
New treatment option for Cerebrovascular Accident
Official title Neurofeedback-EEG Rehabilitation Protocol on Motor Recovery in the Subacute Phase Post-stroke (CUSTOM-NF-STROKE)
ClinicalTrials.gov ID: NCT06212219
What this study is testing
- What it's testing
- Neurofeedback (NF) is a procedure for providing direct sensory feedback (in the form of visual, auditory or tactile stimulation) to a patient about their brain activity when performing a cognitive or motor task. This NF aims to allow the patient to become aware of this brain activity and thus learn to modulate it voluntarily in order to improve the performance obtained on the task.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 99
You may be able to join if
- Man, woman, over 18 years old
- Motor deficit of the upper limb type of hemiplegia, secondary to a hemorrhagic or ischemic stroke authenticated by brain imaging (MRI or CT)
- Post-stroke patients in the subacute phase, between 15 days and 6 months after the stroke
- Correct or corrected vision allowing reading at a distance of 0 to 2m
- Ability to maintain a seated position for 1 hour
You likely can't join if
- Minors (age \< 18 years)
- Phasic disorder limiting comprehension corresponding to a Boston Diagnostic Aphasia Examination (BDAE) score \< 4
- Attentional disorder not allowing sufficient attention to be maintained for 1 hour
- History of known stroke with motor sequelae.
- Known peripheral neurological pathology affecting the paretic upper limb.
- Other known central neurological pathology
See the full eligibility criteria
- Man, woman, over 18 years old
- Motor deficit of the upper limb type of hemiplegia, secondary to a hemorrhagic or ischemic stroke authenticated by brain imaging (MRI or CT)
- Post-stroke patients in the subacute phase, between 15 days and 6 months after the stroke
- Correct or corrected vision allowing reading at a distance of 0 to 2m
- Ability to maintain a seated position for 1 hour
- Patient affiliated to a social security scheme or beneficiary of such a scheme
- Informed patient having signed consent
- Minors (age \< 18 years)
- Phasic disorder limiting comprehension corresponding to a Boston Diagnostic Aphasia Examination (BDAE) score \< 4
- Attentional disorder not allowing sufficient attention to be maintained for 1 hour
- History of known stroke with motor sequelae.
- Known peripheral neurological pathology affecting the paretic upper limb.
- Other known central neurological pathology
- Factors hindering EEG acquisition (scalp pathology, abnormal cervico-cephalic movements, cranial metal implants)
- Unstabilized epilepsy
- Refusal to participate in the study
- Protected patient: adult under guardianship, curatorship or other legal protection, deprived of liberty by judicial or administrative decision
- Pregnant, parturient, or breastfeeding patient
The study team makes the final eligibility decision.
Where it's taking place
- Toulouse, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 99 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Toulouse, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.